Lymphoma
Biogen Idec initiates phase III trial of Galiximab for lymphoma
Published in Cancer Weekly, February 27th, 2007
Biogen Idec (BIIB) announced that it has initiated a phase III randomized, double-blind study of an investigational anti-CD80 monoclonal antibody, galiximab, for patients with lymphoma. The trial will compare treatment with galiximab in combination with rituximab (Rituxan) to rituximab in combination with placebo in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed or failed to respond to initial therapy.
The study is a registrational clinical trial being conducted under a Special Protocol Assessment granted by the U.S. Food and Drug Administration (FDA) in July 2006. The study enrolled the first patient in November 2006 at Loyola University...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-02-27)
More Articles from Cancer Weekly
- Cancer Therapy
Biologists identify a major player in cell growth - Cancer Therapy
Improved imaging techniques may help identify breast cancer earlier in overweight women - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Institute Pasteur - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at University of Texas, Department of Cell Biology - Cancer Gene Therapy
Data on cancer gene therapy reported by researchers at Beatson Laboratories - Cancer Gene Therapy
Findings from Tokyo Medical and Dental University broaden understanding of cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
